Form 4: Enliven Therapeutics COO Anish Patel Executes Option Exercise and Stock Sale

Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 6, 2024, Anish Patel, the Chief Operating Officer of Enliven Therapeutics, exercised stock options to acquire 1,133 shares of common stock at a price of $2.48 per share.
• Simultaneously, Patel sold 1,133 shares of common stock at a weighted average price of $20.0551, with individual sales ranging from $19.785 to $20.41.
• Following these transactions, Patel directly owns no shares and indirectly owns 394,027 shares through The Patel / Dong Family Trust Dated August 24 2017, for which he serves as trustee.
• The option exercise and stock sale were conducted under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• After the transaction, Patel directly holds 53,342 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction disclosure under a pre-arranged trading plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 trading plan suggests that the transactions were pre-planned and not based on any material non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.

Key Dates